# OnCo record recurrent-metastatic-hnscc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/recurrent-metastatic-hnscc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "recurrent-metastatic-hnscc" ;
  schema:name "Recurrent or metastatic head and neck squamous cell carcinoma"@en ;
  schema:alternateName "R/M HNSCC"@en, "Advanced head and neck cancer"@en, "Platinum-refractory head and neck cancer"@en ;
  schema:description "When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."@en ;
  schema:url <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Head_and_neck_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Head_and_neck_cancer> ;
  onco:tag "subtype-page", "head-and-neck", "state-page" ;
  onco:related <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/>, <https://onco.cc/cancers/laryngeal-cancer/>, <https://onco.cc/cancers/oral-cavity-cancer/>, <https://onco.cc/cancers/oropharyngeal-cancer/> ;
  onco:drugs <https://onco.cc/drugs/celecoxib/>, <https://onco.cc/drugs/hb-200/> ;
  onco:trials <https://onco.cc/trials/tpextreme/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-048-lancet-2019/>, <https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/>, <https://onco.cc/key-papers/paper-extreme-vermorken-nejm-2008/>, <https://onco.cc/key-papers/paper-tpextreme-lancet-oncol-2021/> ;
  onco:pipeline <https://onco.cc/drugs/petosemtamab/>, <https://onco.cc/trials/liger-hn1/>, <https://onco.cc/trials/nct06496178/>, <https://onco.cc/drugs/ficerafusp-alfa/>, <https://onco.cc/trials/fortifi-hn01/>, <https://onco.cc/trials/nct07807163/>, <https://onco.cc/drugs/mrg003/>, <https://onco.cc/trials/nct05751512/>, <https://onco.cc/trials/nct06601335/>, <https://onco.cc/trials/nct07276399/>, <https://onco.cc/drugs/bnt113/>, <https://onco.cc/drugs/monalizumab/>, <https://onco.cc/drugs/cetuximab-sarotalocan/>, <https://onco.cc/trials/nct06699212/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/cps/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/trials/extreme/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-141/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/cetuximab-sarotalocan/>, <https://onco.cc/technologies/photoimmunotherapy/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/trials/metronomic-vs-cisplatin-tmh/>, <https://onco.cc/trials/low-dose-nivolumab-tmh/>, <https://onco.cc/trials/metro-plus-varanasi/>, <https://onco.cc/technologies/palliative-radiotherapy/> .